SciELO - Brasil - The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health
SciELO - Brasil - The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health
Ultomiris: Can drug innovation be too expensive? - STAT
Patients with rare disorder to get €430,000 drug
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says | Fierce Pharma
When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs - Bloomberg
Alexion's Soliris successor in PNH unlikely to achieve price premium